scPharmaceuticals (SCPH) Competitors

Akebia Therapeutics (NASDAQ:AKBA) and scPharmaceuticals (NASDAQ:SCPH) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, community ranking, media sentiment, analyst recommendations, risk, dividends and valuation.

Does the media prefer AKBA or SCPH?

In the previous week, scPharmaceuticals had 20 more articles in the media than Akebia Therapeutics. MarketBeat recorded 23 mentions for scPharmaceuticals and 3 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 1.46 beat scPharmaceuticals' score of 0.13 indicating that Akebia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akebia Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
scPharmaceuticals	5 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community favor AKBA or SCPH?

Akebia Therapeutics received 259 more outperform votes than scPharmaceuticals when rated by MarketBeat users. However, 67.08% of users gave scPharmaceuticals an outperform vote while only 63.08% of users gave Akebia Therapeutics an outperform vote.

Company	Underperform	Outperform
Akebia Therapeutics	Outperform Votes 422 63.08%	Underperform Votes 247 36.92%
scPharmaceuticals	Outperform Votes 163 67.08%	Underperform Votes 80 32.92%

Do insiders & institutionals have more ownership in AKBA or SCPH?

33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 89.5% of scPharmaceuticals shares are owned by institutional investors. 3.0% of Akebia Therapeutics shares are owned by insiders. Comparatively, 5.5% of scPharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Which has stronger valuation & earnings, AKBA or SCPH?

Akebia Therapeutics has higher revenue and earnings than scPharmaceuticals. Akebia Therapeutics is trading at a lower price-to-earnings ratio than scPharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$184.91M	3.99	-$51.92M	-$0.21	-13.38
scPharmaceuticals	$41.98M	4.20	-$54.81M	-$1.91	-1.75

Which has more risk & volatility, AKBA or SCPH?

Akebia Therapeutics has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Comparatively, scPharmaceuticals has a beta of 0.17, indicating that its stock price is 83% less volatile than the S&P 500.

Do analysts prefer AKBA or SCPH?

Akebia Therapeutics presently has a consensus target price of $6.63, suggesting a potential upside of 135.77%. scPharmaceuticals has a consensus target price of $14.00, suggesting a potential upside of 319.16%. Given scPharmaceuticals' higher probable upside, analysts clearly believe scPharmaceuticals is more favorable than Akebia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.20
scPharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is AKBA or SCPH more profitable?

Akebia Therapeutics has a net margin of -27.07% compared to scPharmaceuticals' net margin of -264.60%. Akebia Therapeutics' return on equity of 0.00% beat scPharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-27.07%	N/A	-20.57%
scPharmaceuticals	-264.60%	-244.93%	-68.56%

Summary

Akebia Therapeutics beats scPharmaceuticals on 12 of the 19 factors compared between the two stocks.